Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients

Daratumumab is active both as a single agent and in combination with other agents in multiple myeloma (MM) patients. However, the majority of patients will develop daratumumab-refractory disease, which carries a poor prognosis. Since daratumumab also has immunomodulatory effects, addition of the PD-...

Full description

Bibliographic Details
Main Authors: Kristine A. Frerichs, Christie P. M. Verkleij, Meletios A. Dimopoulos, Jhon A. Marin Soto, Sonja Zweegman, Mary H. Young, Kathryn J. Newhall, Tuna Mutis, Niels W. C. J. van de Donk
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
immunotherapy
multiple myeloma
PD-L1
CD38
daratumumab
checkpoint inhibitor
Online Access:https://www.mdpi.com/2072-6694/13/10/2452

Internet

https://www.mdpi.com/2072-6694/13/10/2452

Similar Items